Emotion regulation skills training as an adjunctive treatment to narrative exposure therapy for posttraumatic stress disorder (PTSD) in refugees: a pilot randomized controlled trial.

Eur J PsychotraumatolApr 8, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Angela Nickerson, Marylene Cloitre, Frank Neuner et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial compared Skills Training in Affective and Interpersonal Regulation for Refugees plus Narrative Exposure Therapy (STAIR-R + NET) with Supportive Problem-Solving plus NET in 71 refugees with PTSD. The primary outcome was clinician-assessed PTSD severity. There were no significant between-group differences at mid-treatment, post-treatment, or 3-month follow-up. Both groups improved by follow-up: clinician-assessed PTSD symptoms showed large within-group changes (STAIR-R + NET, g = -1.41; SPS + NET, g = -1.54, p < .001). Exploratory analyses suggested greater benefits from STAIR-R + NET among participants with high insecurity.

Key findings

  • No significant between-group differences were found at mid-treatment, post-treatment, or 3-month follow-up.
  • At 3-month follow-up, clinician-assessed PTSD symptoms improved in both groups (STAIR-R + NET, g = -1.41; SPS + NET, g = -1.54, p < .001).
  • Among participants with high insecurity (n = 16), exploratory analyses favored STAIR-R + NET across self-reported PTSD, depression, emotion regulation, relationships, and quality of life.

Why it matters

The findings indicate that refugees in both treatment conditions experienced reduced PTSD symptoms, while adding emotion regulation skills training did not produce an overall advantage over supportive problem-solving when each was paired with NET. The exploratory results raise the possibility that environmental insecurity may be relevant to treatment response, underscoring the value of evaluating outcomes across differing circumstances.

What to keep in mind

This was a pilot trial, and the high-insecurity subgroup was small (n = 16); the authors state that the subgroup findings require replication.

Source

Published in Eur J Psychotraumatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.